Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 7/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 4/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486158 | 0.89 | DGAT1 (0.37) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL19295090 | 0.85 | LPL (0.40) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL19295096 | 0.83 | DGAT1 (0.37) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL17486200 | 0.82 | DGAT1 (0.34) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL19295097 | 0.81 | PDGFRB (0.39) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL17486021 | 0.81 | DGAT1 (0.36) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL20805747 | 0.81 | DGAT1 (0.38) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL29688284 | 0.80 | DGAT1 (0.52) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL17477815 | 0.80 | DGAT1 (0.52) | LPLLIPGPDGFRBKDRDGAT1 | |
| SCHEMBL15936842 | 0.79 | FEN1 (0.48) | LPLLIPGPDGFRBKDRALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174890-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-9853228-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-26 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| US-20170250353-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2017-08-31 | — | — | US | disclosed |
| WO-2016015815-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170250353-A1 | METAL COMPLEXES | SOD1, AP1M1, AP3M1 | LPL 3163/4885LIPG 3210/4885PDGFRB 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.